医療用RI製造における加速器利用—放射性医薬品メーカーの視点から—

抄録

Medical radioisotopes (RI) are commercially manufactured with cyclotrons as raw material of radiopharmaceutical products. Nihon Medi-Physics, radiopharmaceutical company in Japan, has been developing manufacturing technology of alpha emitting nuclide ²²⁵Ac and positron emitting nuclide ⁸⁹Zr for Theragnostic medical agent. For commercialization of RI, scaling up is required from basic study in academia (kBq–MBq) to commercial mass production (GBq–TBq). Gap of radio activity between them is over thousand times and overcoming of several technological challenges is necessary. Moreover, some other issue such as economic efficiency, quality requirements as medicine, regulatory also severely affect in commercialization. Described here is a part of topics from a speech in The Second Accelerator Symposium held on 12th December 2024.